LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
+4.55%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$151M
AUM Growth
+$151M
(-0.94%)
Cap. Flow
-$2.35M
Cap. Flow
% of AUM
-1.55%
Top 10 Holdings %
Top 10 Hldgs %
93.67%
Holding
25
New
7
Increased
1
Reduced
7
Closed
7
Top Buys
| 1 |
Stoke Therapeutics
STOK
|
$6.74M |
| 2 |
AUTL
Autolus Therapeutics
AUTL
|
$3.18M |
| 3 |
SLN
Silence Therapeutics
SLN
|
$2.32M |
| 4 |
NEUP
Neuphoria Therapeutics Inc. Common Stock
NEUP
|
$2.2M |
| 5 |
C4 Therapeutics
CCCC
|
$1.9M |
Top Sells
| 1 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
$7.06M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$3.14M |
| 3 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$3.04M |
| 4 |
Neurogene
NGNE
|
$2.57M |
| 5 |
Cullinan Oncology
CGEM
|
$1.24M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cabaletta Bio
CABA
$133M
| $32.1M | 21.2% |
2,106,000
-75,377
| -3% | -$1.15M |
|
|
ALPN
2
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $27.5M | 18.21% |
2,404,614
-265,858
| -10% | -$3.04M |
|
3
Merus
MRUS
$4.98B
| $27.1M | 17.94% |
1,150,225
-2,300
| -0.2% | -$54.2K |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $14.8M | 9.8% |
994,161
-210,889
| -18% | -$3.14M |
|
5
TScan Therapeutics
TCRX
$102M
| $13.4M | 8.85% |
5,224,600
| – | – |
|
6
GH Research
GHRS
$837M
| $11.1M | 7.33% |
1,103,178
+133,804
| +14% | +$1.34M |
|
|
7
Stoke Therapeutics
STOK
$1.08B
| $6.74M | 4.46% |
+1,710,154
| New | +$6.74M |
|
|
AUTL
8
Autolus Therapeutics
AUTL
$399M
| $3.18M | 2.1% |
+1,363,025
| New | +$3.18M |
|
|
PVLA
9
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $2.91M | 1.93% |
9,775,849
| – | – |
|
|
KNTE
10
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $2.8M | 1.85% |
1,997,006
-51,730
| -3% | -$72.4K |
|
|
SLN
11
Silence Therapeutics
SLN
$227M
| $2.32M | 1.53% |
+235,787
| New | +$2.32M |
|
|
NEUP
12
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $2.2M | 1.46% |
+815,512
| New | +$2.2M |
|
|
13
C4 Therapeutics
CCCC
$185M
| $1.9M | 1.25% |
+1,019,230
| New | +$1.9M |
|
|
THRX
14
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $1.89M | 1.25% |
702,415
-54,594
| -7% | -$147K |
|
15
Nektar Therapeutics
NKTR
$568M
| $1.05M | 0.7% |
+1,766,815
| New | +$1.05M |
|
16
Passage Bio
PASG
$22.7M
| $125K | 0.08% |
190,124
-977,219
| -84% | -$643K |
|
17
Zura Bio
ZURA
$133M
| $65.5K | 0.04% |
+9,917
| New | +$65.5K |
|
|
DBVT
18
DBV Technologies
DBVT
$264M
| $24.8K | 0.02% |
18,265
| – | – |
|
19
Athira Pharma
ATHA
$15.3M
| – | – |
-193,573
| Closed | -$571K |
|
|
20
Cullinan Oncology
CGEM
$445M
| – | – |
-115,063
| Closed | -$1.24M |
|
|
CMPS
21
Compass Pathways
CMPS
$424M
| – | – |
-20,114
| Closed | -$167K |
|
22
Structure Therapeutics
GPCR
$1.11B
| – | – |
-23,000
| Closed | -$956K |
|
|
23
Neurogene
NGNE
$264M
| – | – |
-3,094,554
| Closed | -$2.57M |
|
24
Pharvaris
PHVS
$1.39B
| – | – |
-21,225
| Closed | -$321K |
|
|
PRDS
25
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| – | – |
-3,902,434
| Closed | -$7.06M |
|